Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.94 -1.17%

-$0.11 today

Market cap
$1.31B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.67M

Average 3.00M

OCUL Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Ocular Therapeutix, Inc.NASDAQ: OCUL

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin narrows to -865.5%

Operating margin was -865.5% in Q1 FY2026, down 268.0 pp from a year earlier. On a trailing-twelve-month basis it was -575.4%, down 233.3 pp year over year. Over 3 fiscal years it narrowed by 368.3 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 9 analysts of -560.2% for the fiscal year ending Dec 2026, down from -521.0% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-865.5%-339.0 pp QoQ
Last fiscal yearDec 2025
-521.0%-251.5 pp YoY
LTMMar 2026
-575.4%-233.3 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-268.0 pp-151.8 pp+116.2 pp
1 year-251.5 pp-39.2 pp+212.3 pp
3 years-368.3 pp+415.4 pp+783.7 pp
5 years+544.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-521.0%
Year-over-year change
-251.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How OCUL compares with its peers on the latest reported figures

  • OCUL's LTM Mar 2026 operating margin of -575.4% is the 5th highest of the 9 companies compared; the peer median is -748.5%.
  • Its year-over-year change of -233.3 pp is the 7th highest of 8, against a peer median of +8.3 pp.
  • Over three fiscal years its change of -368.3 pp compares with a peer median of +5.1 pp.
OCUL Competitors Peer median
Operating Margin for OCUL and competitors
Company Period LTM level YoY 3-year change
HROWHarrow Health, Inc.LTM Mar 202610.5% +8.3 pp+12.0 pp
BLCOBausch + Lomb CorporationLTM Jun 20267.1% +5.5 pp-1.8 pp
STAASTAAR Surgical CompanyLTM Apr 2026-1.7% +22.5 pp-34.6 pp
GKOSGlaukos CorporationLTM Jun 2026-13.1% +9.2 pp+12.0 pp
OCULOcular Therapeutix, Inc.LTM Mar 2026-575.4% -233.3 pp-368.3 pp
OCGNOcugen, Inc.LTM Mar 2026-1483.9% -222.4 pp+2154.3 pp
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026-3700.9% -3412.9 pp-535.3 pp
OCSOculis Holding AGLTM Mar 2026-16741.0% ——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-18182.8% +26748.2 pp—
KODKodiak Sciences Inc.FY2025— ——
SGPSpyGlass Pharma, Inc. Common StockFY2025— ——
Peer median (excluding OCUL) -748.5%+8.3 pp+5.1 pp

Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue43.52M51.49M58.44M63.72M51.82M
Cost of Revenue4.41M4.54M5.28M5.63M6.57M
Gross Profit39.12M46.95M53.16M58.1M45.25M
Gross Margin89.9%91.2%91.0%91.2%87.3%
Research & Development50.08M53.46M61.06M127.64M197.1M
Selling, General & Admin67.07M72.15M74.49M102.24M118.3M
Operating Expenses117.15M125.61M135.54M229.88M315.39M
Depreciation & Amortization2.42M2.11M2.98M3.79M4.32M
EBITDA2.54M(61.91M)(66.42M)(176.14M)(249.78M)
EBITDA Margin5.8%-120.2%-113.6%-276.4%-482.0%
Operating Income(78.04M)(78.65M)(82.38M)(171.78M)(270.02M)
Operating Margin-179.3%-152.7%-141.0%-269.6%-521.0%
Interest Income33K798K3.98M20.28M18.36M
Interest Expense6.67M7.02M11.34M13.58M11.84M
Other Income / Expenses71.48M7.62M1.65M(21.73M)4.08M
Income Before Tax(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Pre-Tax Margin-15.1%-138.0%-138.1%-303.7%-513.2%
Income Tax Expense00000
Net Income(6.55M)(71.04M)(80.74M)(193.51M)(265.94M)
Net Margin-15.1%-138.0%-138.1%-303.7%-513.2%
EPS (Basic)(1.05)(1.04)(1.09)(1.22)(1.42)
EPS (Diluted)(0.98)(0.97)(1.02)(1.22)(1.42)
Weighted Avg Shares76.39M76.88M79.83M158.27M187.24M
Weighted Avg Shares (Diluted)82.16M82.64M85.6M158.27M187.24M

Ocular Therapeutix, Inc.

NASDAQ:OCUL

Intrinsic Alpha fair value

Locked

Current Price

$5.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.